Key Positives From The Results
The Surveillance & FA business (+29.0% YoY) and Mobility & Healthcare and Others business (+39.6% YoY) achieved double-digit revenue and profit growth, offsetting the decline in the Photography-related business. Combined segment profit from industrial businesses reached JPY 3,013M (up +32.7% from JPY 2,271M in the prior year), expanding their earnings contribution and demonstrating further progress in portfolio diversification.
- Surveillance & FA revenue reached JPY 7,711M (+29.0% YoY), driven by demand for high-definition/high-resolution imaging and the completion of inventory adjustments
- Mobility & Healthcare and Others revenue came in at JPY 8,035M (+39.6% YoY), fueled by expanding ADAS demand and medical lens revenue more than doubling YoY
- Own-brand products posted double-digit revenue growth in the US, Europe, and India; 10+ new product launches planned for 2026
- Favorable FX tailwinds (USD ~+JPY 10, EUR ~+JPY 22) boosted top-line results
- Comprehensive income of JPY 7,641M (+63.3% YoY), supported by JPY +1,500M in foreign currency translation adjustments
Key Concerns From The Results
OPM declined 4.3pt to 17.8% from 22.1% in the prior-year period. The revenue decline in the higher-margin Photography-related business (−8.2%) weighed on overall profitability, compounded by higher SG&A (+7.5% YoY), resulting in operating income of JPY 7,689M (−16.5% YoY) — a double-digit decline.
- Photography-related segment profit of JPY 5,943M (−29.3% YoY), with margin falling 6.4pt from 28.0% to 21.6%
- Sales weakness in certain OEM product models has persisted since 2H of the prior year, with the timing of recovery remaining unclear
- Gross profit margin of 41.9% (vs. 45.3% prior year, −3.4pt); cost reduction initiatives were insufficient to offset the declining mix of Photography-related revenue
- SG&A of JPY 10,441M (+7.5% YoY), pressured by rising personnel costs (salaries and bonuses +JPY 285M) and higher R&D spending (technical research expenses +JPY 212M)
- China market continues to face excess channel inventory in Photography-related products, contributing to revenue decline
Focus Areas / Items To Monitor Going Forward
- Whether the order slump in Photography-related OEM products troughs in 2H. The full-year plan assumes a double-digit revenue and profit recovery in 2H, making the OEM rebound pivotal to guidance achievement
- Sustainability of high growth in Mobility & Healthcare. The pace of continued ADAS lens demand and medical lens expansion will determine the scope for upside to full-year guidance
- Response to Sony's proposal for full subsidiary acquisition and the associated enterprise valuation. Combined with Effissimo's stake accumulation (most recently 17.38%), attention should be paid to risks of changes in the capital structure
- Specific recovery outlook and customer dynamics for underperforming OEM product models
- Initiatives to restore Photography-related segment margins and target revenue mix between own-brand and OEM
- Sensitivity analysis around 2H assumed FX rates (JPY 160/USD, JPY 180/EUR)
- Expected timeline for resolution of excess inventory in the China market
- Competitive landscape and barriers to entry in the medical lens segment within Mobility & Healthcare
- Roadmap to achieve JPY 120B revenue and JPY 25B operating income targets by 2029 under the next medium-term plan "Value Up29"
- Commercialization timeline and initial revenue assumptions for metasurface near-infrared light sources
- Review schedule and decision criteria of the Special Committee regarding Sony's proposal for full subsidiary acquisition
- Scale and priority areas for M&A strategic investment allocation
- Management's stance on Effissimo's continued stake accumulation
Key Financial Highlights
| Item | Value | YoY |
|---|---|---|
| Revenue | JPY 43,281M | +3.8% |
| Cost of Goods Sold | JPY 25,150M | +10.3% |
| Gross Profit | JPY 18,130M | −4.2% |
| SG&A | JPY 10,441M | +7.5% |
| Operating Income | JPY 7,689M | −16.5% |
| Recurring Profit | JPY 7,741M | −16.5% |
| Net Income Attributable to Owners of Parent Company (Interim) | JPY 6,197M | −9.9% |
| EPS | JPY 38.42 | −9.6% |
| Comprehensive Income | JPY 7,641M | +63.3% |
| Gross Profit Margin | 41.9% | −3.4pt |
| Operating Income Margin | 17.8% | −4.3pt |
Revenue grew +3.8%, but COGS rose +10.3% — outpacing top-line growth — resulting in a 3.5pt deterioration in gross margin. Combined with higher SG&A (+7.5%), operating income posted a double-digit decline. The absence of a special loss recorded in the prior-year period (JPY 414M loss on sale of investment securities) limited the net income decline to −9.9%.
Performance By Business Segment
Of three segments, only Photography-related posted revenue and profit declines, while both industrial segments delivered double-digit revenue and profit growth. The Photography-related revenue mix declined to 63.6% (from 71.9% in the prior year, −8.3pt), with the industrial share rising accordingly. By region, North America surged +61.7% (JPY 3,882M → JPY 6,282M) and Europe grew +12.6%, while Asia declined −16.1%. The Asia decline reflected lower Photography-related OEM revenue and excess inventory in China.
Segment Performance Table
| Segment | Revenue | YoY | Operating Income | YoY | Margin |
|---|---|---|---|---|---|
| Photography-Related | JPY 27,534M | −8.2% | JPY 5,943M | −29.3% | 21.6% |
| Surveillance & FA | JPY 7,711M | +29.0% | JPY 1,026M | +10.5% | 13.3% |
| Mobility & Healthcare and Others | JPY 8,035M | +39.6% | JPY 1,987M | +48.0% | 24.7% |
| Adjustments | - | - | −JPY 1,268M | - | - |
| Total | JPY 43,281M | +3.8% | JPY 7,689M | −16.5% | 17.8% |
- Mobility & Healthcare And Others: Revenue +39.6%, profit +48.0%. Automotive camera lenses for ADAS applications posted double-digit growth, aided by the China market recovery. Medical lenses more than doubled YoY, driven by expanded rigid endoscope lineups and strong demand for fluorescence filters
- Surveillance & FA: Revenue +29.0%. Surveillance camera lenses performed well, primarily in developed markets, on rising high-definition/high-resolution demand; FA/machine vision lenses also recovered as inventory adjustments ran their course
- Photography-Related Own-Brand: Despite declines in China, double-digit growth in the US, Europe, and India secured overall revenue growth. Launched the large-aperture standard zoom A078 (Sony E / Nikon Z mount) in March
- Photography-Related OEM: Sales weakness in certain contracted models has persisted since 2H of the prior year, driving the decline in the broader Photography-related segment. Asia-directed revenue fell sharply to JPY 13,141M (from JPY 18,148M, −27.6%)
- Photography-Related Own-Brand China: Revenue declined as excess market inventory continued to weigh
Progress Versus Full-Year Guidance
Revenue progress versus full-year guidance stands at 46.5%, with operating income at 41.6%. Although 1H saw profit declines due to lower Photography-related OEM revenue, the company is maintaining its plan for a double-digit revenue and profit recovery in 2H. Assumed FX rates were revised to JPY 160/USD (from JPY 148) and JPY 180/EUR (from JPY 175), resulting in a JPY 2,000M upward revision to revenue guidance, while profit guidance was left unchanged. The plan is 2H-weighted, with achievement contingent on an OEM recovery and sustained industrial business growth.
| Item | Value (2Q Cumulative) | Full-Year Forecast | Progress Rate |
|---|---|---|---|
| Revenue | JPY 43,281M | JPY 93,000M | 46.5% |
| Operating Income | JPY 7,689M | JPY 18,500M | 41.6% |
| Recurring Profit | JPY 7,741M | JPY 18,500M | 41.8% |
| Net Income | JPY 6,197M | JPY 13,690M | 45.3% |
- Photography-related revenue is typically 2H-weighted, driven by the year-end holiday selling season (4Q). The company's plan also assumes this seasonal skew
Changes To Guidance
Full-year revenue guidance was revised upward from JPY 91,000M to JPY 93,000M (+2.2%). The revision reflects stronger-than-expected Mobility & Healthcare and Others performance and the upward adjustment in assumed FX rates toward weaker yen levels (USD: JPY 148 → JPY 160, EUR: JPY 175 → JPY 180). Operating income, recurring profit, and net income guidance were left unchanged.
- Revenue: JPY 91,000M → JPY 93,000M (+JPY 2,000M)
- Operating Income: JPY 18,500M (unchanged)
- Recurring Profit: JPY 18,500M (unchanged)
- Net Income: JPY 13,690M (unchanged)
- Rationale: Higher revenue outlook driven by 1H outperformance in Mobility & Healthcare and revision of assumed FX rates toward weaker yen. Profit guidance held steady to account for rising procurement and logistics costs stemming from the deteriorating Middle East situation
Commentary On Shareholder Returns
No change to the FY12/2026 dividend forecast. Interim dividend of JPY 20.00, year-end dividend of JPY 31.00 (forecast), for a full-year total of JPY 51.00. The prior fiscal year (FY12/2025) annual dividend was JPY 36.25 on a stock-split-adjusted basis, representing a planned increase of JPY +14.75 (+40.7%).
Financial Position
Equity ratio remains elevated at 81.8% (vs. 81.0% at prior fiscal year-end), maintaining a virtually debt-free balance sheet. Cash and cash equivalents of JPY 34,633M ensure ample liquidity.
- Key Figures
- Leverage Metrics
| Item | Value | Additional Information |
|---|---|---|
| Total Assets | JPY 109,240M | +JPY 3,194M vs. prior FYE (+3.0%) |
| └ Total Current Assets | JPY 72,699M | +JPY 2,006M vs. prior FYE |
| └ Total Non-Current Assets | JPY 36,541M | +JPY 1,188M vs. prior FYE |
| Cash and Cash Equivalents | JPY 34,633M | −JPY 738M vs. prior FYE (−2.1%) |
| Shareholders' Equity | JPY 89,398M | +JPY 3,487M vs. prior FYE (+4.1%) |
| Interest-Bearing Debt | JPY 1,150M | Short-term 798→862, Long-term 247→288 |
| └ Short-Term Borrowings | JPY 862M | - |
| └ Long-Term Borrowings | JPY 288M | Of which JPY 171M is ESOP trust borrowings |
| Investment Securities | JPY 9,211M | +JPY 214M vs. prior FYE |
| EBITDA | JPY 9,536M | Operating income 7,689 + Depreciation 1,847 |
News Released Alongside The Earnings Announcement
None
Major Announcements During The Quarter
- 2026/06/16Announced the outline of next medium-term plan "Value Up29," targeting revenue exceeding JPY 200B by 2035 and revenue exceeding JPY 120B / operating income exceeding JPY 25B / ROE exceeding 20% by 2029. The plan positions Tamron's transformation into a comprehensive optical & sensing solutions company Notice Regarding Renewal of Long-Term Vision Quantitative Targets and Formulation of Next Medium-Term Management Plan "Value Up29" Outline
- 2026/06/19Achieved the world's first practical application of a chip-type metasurface near-infrared light source through joint research with Osaka University; sample shipments to begin from autumn 2026. Applications expected in medical, healthcare, and food inspection fields World's First Practical Application of Heat-Resistant Chip-Type "MIM-Structure Metasurface Near-Infrared Light Source"
- 2026/06/24Announced the July 2 launch of the large-aperture standard zoom lens for APS-C, 17-70mm F2.8 (B070), for Nikon Z mount and Canon RF mount Launch of Class-Leading Zoom Range Large-Aperture Standard Zoom Lens 17-70mm F2.8 (Model B070) for Nikon Z Mount and Canon RF Mount
- 2026/07/15Announced the August 27 launch of the full-frame large-aperture ultra-wide-angle zoom lens 12-20mm F2.8 (A084) for Sony E mount and Nikon Z mount Launch of Ultra-Wide-Angle Zoom Lens "12-20mm F2.8 (Model A084)" for Sony E Mount and Nikon Z Mount
- 2026/07/30Disclosed receipt of a non-binding proposal from Sony regarding full subsidiary acquisition; a Special Committee has been established to review the proposal Regarding Certain Media Reports Concerning the Company
Large-Shareholding Filings / Material Proposals Over The Past Year
- Effissimo Capital Management: 12.04% → 17.38% (Oct 23, 2025 – Apr 7, 2026; stake increased incrementally through 5 amendment filings) — Pure investment (partly client asset management under discretionary investment agreements)
- 13.06% (filed Oct 23, 2025)
- 14.12% (filed Dec 10, 2025)
- 15.30% (filed Feb 17, 2026)
- 16.34% (filed Mar 11, 2026)
- 17.38% (filed Apr 7, 2026)
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.